Times Microwave Systems Introduces Bundled, Multiport Cable Assemblies for 5G

Times Microwave Systems, the preeminent brand in innovative RF and microwave interconnect assemblies, cables, and connectors, introduced its TMQ4™ and TMQ5™ bundled cable assemblies for 5G.

These new solutions combine industry-standard four and five conductor MQ4 and MQ5 connectors with Times Microwave’s high-end coaxial cables. It solves the challenges associated with the ever-increasing number of RF inputs required by the MIMO antennas commonly used to accomplish the densification needs of 5G networks.

The increasing demand for high coverage MIMO antennas used in 5G applications has led to substantial growth in RF ports. Furthermore, 5G antennas are shrinking as higher frequency bands need to accommodate larger bandwidth requirements, translating into more antennas in a smaller space. This densification creates numerous challenges related to installation, torquing, ensuring proper weather sealing and more.

The TMQ4 and TMQ5 bundled coaxial cable solution design dramatically reduce the number of individual connections hooked up while creating a more rugged solution. It checks off all the boxes in terms of antenna port densification, saving a lot of labor with quick and easy fool-proof installation. These harnesses are available with Weather Protection Boots to seal them to IP-67 specification. They also feature excellent UV resistance, adding to the assembly’s durability for long-term performance.

Available with Times Microwave’s industry-leading LMR® cables and low PIM options like the SPO and TFT-5G, these bundled solutions are 0.25″ and smaller. They are also available in several other constructions, including corrugated copper outer sheaths and ultra-flexible flat braid constructions.

Extruded polyethylene fillers create a round cable for optimal weather sealing and clamping, finished with one of several jacket material options for the most demanding applications. The TMQ4 and TMQ5 cluster connectors are also keyed with a color code on the outer coupling nut to make engagement quick and easy. In addition to the male-to-male bundled harness, the female bulkhead connector is also available as a finished assembly ready to be installed into the box and engaged with the printed circuit board.

“The TMQ4 and TMQ5 bundled cables not only improve aesthetics but also reduce labor cost and offer a more rugged solution with better UV resistance and weatherproofing,” said Kevin Moyher, Product Manager at Times Microwave. “Times has a long history of building quality cables and connectors, along with the expertise, processes, techniques, and materials to create custom solutions that solve the specific needs of our customers, and the new TMQ4 and TMQ5 solution is a strong example of that innovation.” A simple and smart part number system, detailed on Times’ new brochure, makes quoting, ordering, and manufacturing easy. All assemblies are made to order and are available as soon as three weeks.

In-house engineering and manufacturing capabilities enable Times Microwave to deliver RF products that meet the most demanding requirements, including customized product design, installation, regulatory compliance, and performance improvement solutions. Most importantly, as a manufacturer with fully integrated design, production, assembly, and testing capabilities, Times Microwave can deliver RF interconnect solutions from conception through testing and production.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy